Observational studyFrontiers in endocrinology2026
Children with craniopharyngioma resection had better response to recombinant human growth hormone therapy than those with idiopathic short stature.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare growth response and rhGH dosage requirements between children with craniopharyngioma post-resection (CP group, n=18) and those with idiopathic short stature (ISS group, n=18). Methods: A retrospective analysis (2010-2020) was conducted on pediatric patients who received rhGH therapy. Key parameters compared between CP and ISS groups included: growth velocity (GV), rhGH dose (IU/kg/d), height, height standard deviation score (HtSDS), IGF-1 standard deviation score (IGF-1 SDS), body mass index (BMI), bone age (BA) and bone age to chronological age ratio (BA/CA). Results: CP patients were older at baseline with lower HtSDS and BA/CA. Both groups had similar annual growth velocities over three years. The CP group achieved comparable height gains with half the rhGH dose of the ISS group. IGF-1 SDS increased in CP but decreased in ISS, normalizing in both. Long-term, CP patients maintained lower BA/CA and achieved higher terminal height. Conclusion: In this observational cohort, children with CP received approximately half the rhGH dose used in children with ISS, yet achieved comparable growth velocity and greater near-adult height.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.